Skip to main content
Tags: moderna | merck | skincancer | treatment | mrna

Moderna, Merck: MRNA Therapy Cuts Skin Cancer by 49 Percent

By    |   Saturday, 16 December 2023 11:21 AM EST

Moderna and Merck have released data, according to their press release, showing a reduced "risk of recurrence or death by 49%" in patients with skin cancer.

The study involved 157 patients with high-risk stage III/IV melanoma. The patients underwent surgery to remove cancerous growths. One group of patients received a dose of one milligram of the mRNA treatment every three weeks for nine doses and 200 milligrams of Keytruda, Merck's monoclonal antibody treatment, every three weeks for about a year.

"We are committed to driving research forward for innovative modalities in earlier stages of cancer, where we can make the most meaningful impact for patients, by combining Merck's expertise in immuno-oncology with Moderna's innovative mRNA technology," Dr. Marjorie Green of Merck Research Laboratories said. "We are pleased to see the results from this planned analyses on recurrence-free survival for V940 (mRNA-4157), and look forward to working with Moderna in expanding our clinical development program for the individualized neoantigen therapy."

Moderna's stock fell 50% this year, but on Thursday, its shares rose 12% to $87.93 in mid-day trading, according to CBS News.

Nick Koutsobinas

Nick Koutsobinas, a Newsmax writer, has years of news reporting experience. A graduate from Missouri State University’s philosophy program, he focuses on exposing corruption and censorship.

© 2024 Newsmax. All rights reserved.


Newsfront
Moderna and Merck have released data, according to their press release, showing a reduced "risk of recurrence or death by 49%" in patients with skin cancer.The study involved 157 patients with high-risk stage III/IV melanoma.
moderna, merck, skincancer, treatment, mrna
183
2023-21-16
Saturday, 16 December 2023 11:21 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Interest-Based Advertising | Do not sell or share my personal information

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved
Download the NewsmaxTV App
Get the NewsmaxTV App for iOS Get the NewsmaxTV App for Android Scan QR code to get the NewsmaxTV App
NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved